321 results on '"Montalbán, Xavier"'
Search Results
2. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course
3. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
4. Optic chiasm manual and automated measurements in sub-acute optic neuritis with OCT and MRI correlations
5. Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis
6. Validation of the Spanish version of DYsphagia in MUltiple Sclerosis questionnaire (DYMUS)
7. Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI
8. Multiple sclerosis progression: time for a new mechanism-driven framework
9. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
10. Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice
11. Detection of lesions in the optic nerve with magnetic resonance imaging using a 3D convolutional neural network
12. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
13. 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
14. Modelling multiple sclerosis using induced pluripotent stem cells
15. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
16. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
17. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study
18. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
19. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
20. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE
21. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
22. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
23. Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions
24. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders
25. Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response
26. The role of the cerebellum in multiple sclerosis—150 years after Charcot
27. Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation
28. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
29. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study
30. MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry
31. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects
32. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis
33. Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis
34. Time to Qualifying Relapse by Previous Disease-Modifying Therapy Status in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets Over 2 Years in the CLARIFY-MS Study
35. Update on Long-Term Efficacy and Safety of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Over 5 Years from an Ongoing Phase 2 Open-Label Extension
36. Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)
37. Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis
38. Effect of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, on Patient-Reported Vitality and Mental Health in Patients with Relapsing Multiple Sclerosis in a Phase 2 Trial
39. Investigation of Changes in Lymphocyte Subset Counts and their Relationship with MRI Outcomes in the Magnify-MS Study
40. Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis (P5-3.010)
41. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs
42. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
43. Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design
44. Corrigendum to “Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis” [Journal of the Neurological Sciences 449C (2023) Start page–End page/JOTNS D-23-00048R2]
45. Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation
46. Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis
47. Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response.
48. Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method
49. Breast regression protein-39 is not required for experimental autoimmune encephalomyelitis induction
50. sj-docx-1-tan-10.1177_17562864231180734 – Supplemental material for Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.